These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37499587)

  • 41. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer's disease spectrum patients.
    Shigemoto Y; Sone D; Maikusa N; Okamura N; Furumoto S; Kudo Y; Ogawa M; Takano H; Yokoi Y; Sakata M; Tsukamoto T; Kato K; Sato N; Matsuda H
    Brain Behav; 2018 Dec; 8(12):e01145. PubMed ID: 30358161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
    J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease.
    Hays CC; Zlatar ZZ; Wierenga CE
    Cell Mol Neurobiol; 2016 Mar; 36(2):167-79. PubMed ID: 26898552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
    Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
    JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
    Guo T; Landau SM; Jagust WJ;
    Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings.
    Gonzalez C; Mimmack KJ; Amariglio RE; Becker JA; Chhatwal JP; Fitzpatrick CD; Gatchel JR; Johnson KA; Katz ZS; Kuppe MK; Locascio JJ; Udeogu OJ; Papp KV; Premnath P; Properzi MJ; Rentz DM; Schultz AP; Sperling RA; Vannini P; Wang S; Marshall GA
    J Alzheimers Dis; 2023; 94(1):217-226. PubMed ID: 37212093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease.
    Senda M; Ishii K; Ito K; Ikeuchi T; Matsuda H; Iwatsubo T; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikari Y; Niimi Y; Arai H; Tamaoka A; Arahata Y; Itoh Y; Tachibana H; Ichimiya Y; Washizuka S; Odawara T; Ishii K; Ono K; Yokota T; Nakanishi A; Matsubara E; Mori H; Shimada H
    J Prev Alzheimers Dis; 2021; 8(4):495-502. PubMed ID: 34585225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
    Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
    JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimer's Disease.
    Klein J; Yan X; Johnson A; Tomljanovic Z; Zou J; Polly K; Honig LS; Brickman AM; Stern Y; Devanand DP; Lee S; Kreisl WC
    J Alzheimers Dis; 2021; 80(3):1051-1065. PubMed ID: 33646153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
    Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
    J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment.
    Brown EE; Rashidi-Ranjbar N; Caravaggio F; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Fischer CE; Flint A; Mah L; Herrmann N; Bowie CR; Voineskos AN; Graff-Guerrero A;
    J Neuroimaging; 2019 Nov; 29(6):721-729. PubMed ID: 31270885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alzheimer disease biomarkers are associated with body mass index.
    Vidoni ED; Townley RA; Honea RA; Burns JM;
    Neurology; 2011 Nov; 77(21):1913-20. PubMed ID: 22105948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
    Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
    JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Financial Capacity and Regional Cerebral Tau in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia.
    Gonzalez C; Tommasi NS; Briggs D; Properzi MJ; Amariglio RE; Marshall GA;
    J Alzheimers Dis; 2021; 79(3):1133-1142. PubMed ID: 33386806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.